Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
-0.6%  /
76.8%
22.6x
34.5x
0.4x
1.7%
8.3%
..
0.0%
16.9% 
22.4%  /
29.1%
>200x
>200x
0.4x
-2.7%
-6.8%
..
0.0%
-25.8% 
0.0%  /
26.9%
>200x
2.3x
3.5x
-52.7%
260.7%
..
0.0%
23.4% 
21.0%  /
13.2%
>200x
>200x
7.2x
-15.7%
-1.2%
..
0.0%
-0.2% 
10.3%  /
11.0%
25.7x
18.3x
4.6x
17.9%
14.5%
2027-02-04
0.0%
3.4% 
11.3%  /
6.3%
5.9x
8.4x
1.2x
20.9%
-1.0%
2027-02-04
0.0%
-1.1% 
4.8%  /
6.1%
4.8x
7.9x
0.9x
16.1%
17.3%
2027-02-04
0.0%
78.6% 
-20.1%  /
-1.8%
7.8x
8x
1.9x
23.9%
6.8%
2027-02-27
0.0%
3.8% 
0.0%  /
-3.7%
9.6x
12.1x
8.1x
83.7%
-88.6%
2027-02-24
14.4%
-16.2% 
0.0%  /
-8.3%
>200x
5x
0.3x
-8.3%
0.0%
..
0.0%
--- 
20.5%  /
-9.2%
>200x
>200x
0.5x
-35.7%
-9.9%
..
0.0%
-15.5% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2026-11-14
#reports #SRG

[Seritage Growth Properties](https://eninvs.com/all.php?name=SRG) (REIT — Retail) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204414)
(2026-05-15, After Market Close):

- Revenue -33.3% YoY (vs -50.0% in previous quarter and historical rate -34.7%)
- EBITDA margin -200.0% increased compared to -366.7% same period last year
- Net Debt increased by $15 mln over the past reporting period (17.5% of market cap)
- FCF (LTM) -$0 bln (negative), 2.3% of market cap
- EV/Sales multiple is 10.4x

2026-11-14
#reports #SGRP

[SPAR Group](https://eninvs.com/all.php?name=SGRP) (Specialty Business Services) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204389)
(2026-05-12, Before Market Open):

- Revenue -20.9% YoY (vs -2.6% in previous quarter and historical rate -18.2%)
- P/S multiple is 0.1x
- Price to book: 0.7x
2026-11-14
#reports #RHE

[Regional Health Properties](https://eninvs.com/all.php?name=RHE) (Medical Care Facilities) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204388)
(2025-04-03):

- Revenue +66.7% YoY (vs +140.0% in previous quarter and historical rate +81.8%)
- EBITDA -80% YoY (vs -100.0% in previous quarter)
- EBITDA margin 4.0% decreased compared to 33.3% same period last year
- Net Debt decreased by $1 mln over the past reporting period (20377.5% of market cap)
- FCF (LTM) -$0.1 bln (negative), 2669447.3% of market cap
- EV/EBITDA multiple is 21.5x compared to historical level (75th percentile) of 17.5x
- EV/Sales multiple is 1.4x

2026-11-14
#reports #OPRX

[OptimizeRx Corporation](https://eninvs.com/all.php?name=OPRX) (Health Information Services) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204408)
(2026-05-12, After Market Close):

- Revenue +10% YoY (vs -25.0% in previous quarter and historical rate +11.6%)
- EBITDA margin 18.2% increased compared to -20.0% same period last year
- Net Debt decreased by $4 mln over the past reporting period (2.9% of market cap)
- EV/Sales multiple is 1.6x

2026-11-14
#reports #NVFY

[Nova LifeStyle](https://eninvs.com/all.php?name=NVFY) (Furnishings, Fixtures and Appliances) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204409)
(2025-08-14):

- Revenue +200% YoY (vs 0.0% in previous quarter and historical rate +9.0%)
- EBITDA margin -16.7% increased compared to -50.0% same period last year
- Net Debt decreased by $1 mln over the past reporting period (11.8% of market cap)
- EV/Sales multiple is 0.3x

2026-11-14
#reports #NKTR

[Nektar Therapeutics](https://eninvs.com/all.php?name=NKTR) (Medicines developer) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204454)
(2026-03-12, After Market Close):

- Revenue -25% YoY (vs -9.1% in previous quarter and historical rate -13.3%)
- EBITDA margin -644.4% decreased compared to -266.7% same period last year
- Net Debt increased by $66 mln over the past reporting period (5.2% of market cap)
- FCF (LTM) +$0.4 bln (positive), 33.6% of market cap
- EV/Sales multiple is 14.1x

2026-11-14
#reports #MITQ

[Moving iMage Technologies, Inc.](https://eninvs.com/all.php?name=MITQ) (Communication Equipment) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204424)
(2026-05-14, Before Market Open):

- Revenue 0% YoY (vs -16.7% in previous quarter and historical rate -4.7%)
- Net Debt decreased by $3 mln over the past reporting period (53.3% of market cap)
- FCF (LTM) +$0 bln (positive), 17.8% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 5x
- EV/Sales multiple is 0x

2026-11-14
#reports #HCTI

[Healthcare Triangle, Inc.](https://eninvs.com/all.php?name=HCTI) (Health Information Services) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204429)
(2025-11-13):

- Revenue +200% YoY (vs +125.0% in previous quarter and historical rate +24.9%)
- EBITDA margin -22.2% increased compared to -100.0% same period last year
- Net Debt decreased by $18 mln over the past reporting period (209.9% of market cap)
- FCF (LTM) -$0 bln (negative), 46.6% of market cap
- EV/Sales multiple is 0.4x

2026-11-14
#reports #FTHM

[Fathom](https://eninvs.com/all.php?name=FTHM) (Real Estate Services) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204423)
(2026-05-29, After Market Close):

- Revenue -4.3% YoY (vs -1.1% in previous quarter and historical rate +11.5%)
- EBITDA margin -18.0% decreased compared to -3.2% same period last year
- Net Debt decreased by $3 mln over the past reporting period (103.6% of market cap)
- FCF (LTM) -$0 bln (negative), 276.3% of market cap
- EV/Sales multiple is 0x

2026-11-14
#reports #FBIOP

[Fortress Biotech](https://eninvs.com/all.php?name=FBIOP) (Biotechnology) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204407)
(2026-03-31):

- Revenue +46.2% YoY (vs +6.7% in previous quarter and historical rate +9.5%)
- EBITDA -158.3% YoY (vs -600.0% in previous quarter and historical rate +26.6%)
- EBITDA margin -36.8% decreased compared to 92.3% same period last year
- Net Debt decreased by $96 mln over the past reporting period (19.6% of market cap)
- FCF (LTM) -$0 bln (negative), 2.0% of market cap
- EV/Sales multiple is 5.7x

2026-11-14
#reports #BYFC

[Broadway Financial Corporation](https://eninvs.com/all.php?name=BYFC) (Banks — Regional) reported for [2026 q3](https://eninvs.com/press_release.php?ticker=BYFC&q=2026 q3&id=983104)
(2026-11-13, After Market Close):

- Revenue +25% YoY (vs -47.1% in previous quarter and historical rate +15.8%)
- Net Income margin 10.0% decreased compared to 12.5% same period last year
- P/S multiple is 2.9x
- Price to book: 0.4x
2026-11-14
#reports #BFRI

[Biofrontera Inc.](https://eninvs.com/all.php?name=BFRI) (Drug Manufacturers — Specialty and Generic) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204435)
(2026-03-19, Before Market Open):

- Revenue 0% YoY (vs +33.3% in previous quarter and historical rate +26.6%)
- EBITDA margin -66.7% decreased compared to -55.6% same period last year
- Net Debt increased by $5 mln over the past reporting period (39.8% of market cap)
- FCF (LTM) -$0 bln (negative), 47.7% of market cap
- EV/Sales multiple is 0.5x

2026-11-14
#reports #AIRI

[Air Industries Group](https://eninvs.com/all.php?name=AIRI) (Aerospace and Defense) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204390)
(2026-03-27, After Market Close):

- Revenue +103835.7% YoY (vs +92169.2% in previous quarter and historical rate +48.4%)
- EBITDA margin 8.9% increased compared to 0.0% same period last year
- Net Debt increased by $191 mln over the past reporting period (1568.1% of market cap)
- FCF (LTM) -$0 bln (negative), 8.2% of market cap
- EV/EBITDA multiple is 16.7x compared to historical level (75th percentile) of 16.5x
- EV/Sales multiple is 0.8x

2026-11-14
#reports #FBIO

[Fortress Biotech](https://eninvs.com/all.php?name=FBIO) (Biotechnology) reported for 2026 q3
(2026-03-31, After Market Close):

- Revenue +5.6% YoY (vs +18.8% in previous quarter and historical rate +1.7%)
- EBITDA margin -31.6% increased compared to -33.3% same period last year
- EV/Sales multiple is 0.7x

2026-11-13
#reports #TAL
@ china , @ edtech

[TAL Education](https://eninvs.com/all.php?name=TAL) (Educational service provider) reported for 2026 q3
(2026-04-23, Before Market Open):

- Revenue -7.1% YoY (vs -9.0% in previous quarter and historical rate -6.0%)
- EBITDA -72.2% YoY (vs -52.4% in previous quarter)
- EBITDA margin 7.7% decreased compared to 25.7% same period last year
- Net Debt decreased by $13 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0 bln (positive), 0.4% of market cap
- EV/EBITDA multiple is 89.1x compared to historical level (75th percentile) of 646x
- EV/Sales multiple is 24.6x

2026-11-13
#reports #YETI

[YETI](https://eninvs.com/all.php?name=YETI) (Goods for outdoor activities manufacturer) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204311)
(2026-05-14, Before Market Open):

- Revenue +4.3% YoY (vs +8.5% in previous quarter and historical rate +8.4%)
- EBITDA +11.8% YoY (vs +44.0% in previous quarter and historical rate +32.4%)
- EBITDA margin 14.9% increased compared to 13.9% same period last year
- Net Debt decreased by $43 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) -$0 bln (negative), 0.5% of market cap
- EV/EBITDA multiple is 9.8x compared to historical level (75th percentile) of 13.8x
- EV/Sales multiple is 1.5x

2026-11-13
#reports #XBIO

[Xenetic Biosciences](https://eninvs.com/all.php?name=XBIO) (Biotechnology) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204302)
(2026-03-12, Before Market Open):

- Revenue -29.4% YoY (vs +12.0% in previous quarter and historical rate +11.0%)
- EBITDA margin -238.6% decreased compared to -52.2% same period last year
- Net Debt increased by $662 mln over the past reporting period (17019.4% of market cap)
- FCF (LTM) +$2.4 bln (positive), 60416.3% of market cap
- EV/EBITDA multiple is 5.4x compared to historical level (75th percentile) of 7.4x
- EV/Sales multiple is -2x

2026-11-13
#reports #WWW

[Wolverine World Wide](https://eninvs.com/all.php?name=WWW) (Clothing/shoes/accessories manufacturer) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204269)
(2026-05-14, Before Market Open):

- Revenue +7.4% YoY (vs +6.8% in previous quarter and historical rate -4.4%)
- EBITDA +76.7% YoY (vs +9.4% in previous quarter and historical rate +38.9%)
- EBITDA margin 21.0% increased compared to 12.8% same period last year
- Net Debt decreased by $50 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) +$0.2 bln (positive), 8.0% of market cap
- EV/EBITDA multiple is 9.4x compared to historical level (75th percentile) of 13x
- EV/Sales multiple is 1.2x

2026-11-13
#reports #VRME

[VerifyMe](https://eninvs.com/all.php?name=VRME) (Security and Protection Services) reported for 2026 q3
(2026-05-15, Before Market Open):

- Revenue +40% YoY (vs -60.0% in previous quarter and historical rate -18.0%)
- EBITDA margin -128.6% decreased compared to 0.0% same period last year
- Net Debt increased by $4 mln over the past reporting period (4.1% of market cap)
- FCF (LTM) +$0 bln (positive), 2.0% of market cap
- EV/Sales multiple is 7.4x

2026-11-13
#reports #VNRX

[VolitionRx Limited](https://eninvs.com/all.php?name=VNRX) (Diagnostics and Research) reported for [2026 q3](https://eninvs.com/press_release.php?source=sec&form_type=10&id=204382)
(2026-05-15, After Market Close):

- Revenue +157.4% YoY (vs -2.0% in previous quarter and historical rate +77.8%)
- EBITDA margin -195.5% increased compared to -774.0% same period last year
- Net Debt decreased by $3.1 bln since the start of the year (15879.8% of market cap)
- FCF (LTM) +$3.6 bln (positive), 18066.5% of market cap
- EV/Sales multiple is 1.8x

2026-11-13
#reports #TWST

[Twist Bioscience](https://eninvs.com/all.php?name=TWST) (Medical services provider) reported for 2026 q3
(2026-05-04, Before Market Open):

- Revenue +28.3% YoY (vs +22.9% in previous quarter and historical rate +23.5%)
- EBITDA margin -16.5% increased compared to -27.3% same period last year
- Net Debt decreased by $414 mln over the past reporting period (5.8% of market cap)
- FCF (LTM) -$0.1 bln (negative), 1.2% of market cap
- EV/Sales multiple is 14.5x